Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR031 in Advanced Hepatocellular Carcinoma
NCT05155189Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Feb 2022
- Primary completion
- May 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT011 in hepatocellular carcinoma (HCC) (4 arms), sponsored by Zhejiang University. Primary endpoints: Treatment-Emergent Adverse Events at 12 months and Adverse Events of Special Interest at 12 months. Started Feb 2022; status: recruiting.
02
Drugs
CT011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05155189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155189.